Anacor $5.2 billion acquisition by Pfizer
Davis Polk is advising Anacor Pharmaceuticals, Inc. on its approximately $5.2 billion acquisition by Pfizer Inc. The closing of the transaction, which is expected in the third quarter of 2016, is subject to customary closing conditions, including U.S. antitrust clearance and the tender of a majority of the outstanding shares of Anacor common stock.
Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Pfizer has a global portfolio that includes medicines and vaccines as well as many of the world’s best-known consumer health care products.
The Davis Polk corporate team includes partners Michael Davis and H. Oliver Smith and associates Evan Rosen and Reid B. Fitzgerald. Partner Edmond T. FitzGerald and counsel Cynthia Akard are providing executive compensation advice. Partner Michael Kaplan is providing capital markets advice. Partner Mark M. Mendez is providing derivatives advice. Partner Michael Mollerus is providing tax advice. Members of the Davis Polk team are based in the New York and Northern California offices.